Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 5
1985 2
1986 23
1987 29
1988 21
1989 33
1990 41
1991 53
1992 35
1993 31
1994 40
1995 45
1996 47
1997 32
1998 40
1999 43
2000 39
2001 35
2002 32
2003 42
2004 50
2005 45
2006 56
2007 55
2008 50
2009 40
2010 35
2011 43
2012 50
2013 52
2014 29
2015 41
2016 34
2017 41
2018 25
2019 22
2020 26
2021 22
2022 17
2023 23
2024 20
2025 24
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,400 results

Results by year

Filters applied: . Clear all
Page 1
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.
Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D'Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foà R, Del Favero A; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program. Bucaneve G, et al. N Engl J Med. 2005 Sep 8;353(10):977-87. doi: 10.1056/NEJMoa044097. N Engl J Med. 2005. PMID: 16148283 Free article. Clinical Trial.
METHODS: We randomly assigned 760 consecutive adult patients with cancer in whom chemotherapy-induced neutropenia (<1000 neutrophils per cubic millimeter) was expected to occur for more than seven days to receive either oral levofloxacin (500 mg daily) or placebo from t …
METHODS: We randomly assigned 760 consecutive adult patients with cancer in whom chemotherapy-induced neutropenia (<1000 neutrophils per …
A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients.
Li Y, Zhu D, Sun S, Chang X, Cao Z, Yang Y, Fu X, Li X, Xu J, Zhu Y, Hui F, Xu X, Chen Z, Peng L, Ma Z, Mo B, Li C, Lv Y, Zhao L, Zhu G, He Y, Liu H, Chen J, Wang Y, Liang Y, Lu Y, Qin Z, Yang H, Zhang M, Wu S, Tong Z, Ye F, Xiao Z, Wang X, Qiu C, Kuang J, Huang H, Wang K, Ying K, Jin F, Lv X, Huang Y, Liu D, Wang W, Zhang Y. Li Y, et al. Int J Antimicrob Agents. 2024 Aug;64(2):107235. doi: 10.1016/j.ijantimicag.2024.107235. Epub 2024 Jun 6. Int J Antimicrob Agents. 2024. PMID: 38851462 Free article. Clinical Trial.
Secondary efficacy and safety were also compared between nemonoxacin and levofloxacin. RESULTS: Overall, 525 patients were randomised and treated with nemonoxacin (n = 349) or levofloxacin (n = 176). The clinical cure rate was 91.8% (279/304) for nemonoxacin and 85. …
Secondary efficacy and safety were also compared between nemonoxacin and levofloxacin. RESULTS: Overall, 525 patients were randomised …
Safety and effectiveness of vonoprazan-based rescue therapy for Helicobacter pylori infection.
Yu J, Lv YM, Yang P, Jiang YZ, Qin XR, Wang XY. Yu J, et al. World J Gastroenterol. 2023 May 28;29(20):3133-3144. doi: 10.3748/wjg.v29.i20.3133. World J Gastroenterol. 2023. PMID: 37346155 Free PMC article. Clinical Trial.
The rates of clarithromycin, metronidazole, and levofloxacin resistance were 91.3% (21/23), 100.0% (23/23), and 60.9% (14/23), respectively. ...In 60.9% (14/23) patients, the H. pylori isolate was resistant to all 3 antibiotics (clarithromycin, metronidazole, and levofl …
The rates of clarithromycin, metronidazole, and levofloxacin resistance were 91.3% (21/23), 100.0% (23/23), and 60.9% (14/23), respec …
Effect of ciprofloxacin vs levofloxacin on QTc-interval and dysglycemia in diabetic and non-diabetic patients.
Saad NA, Elberry AA, Samy Matar H, Hussein RRS. Saad NA, et al. Int J Clin Pract. 2021 May;75(5):e14072. doi: 10.1111/ijcp.14072. Epub 2021 Feb 12. Int J Clin Pract. 2021. PMID: 33559294 Clinical Trial.
OBJECTIVE: To compare intravenous levofloxacin and ciprofloxacin regarding their risk on QTc prolongation and dysglycemia in diabetic and non-diabetic patients. ...CONCLUSION: The present study showed that the risk for QTc prolongation and hyperglycemia was greater with …
OBJECTIVE: To compare intravenous levofloxacin and ciprofloxacin regarding their risk on QTc prolongation and dysglycemia in diabetic …
A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infection.
Li Y, Yin Y, Peng X, Zheng H, Fu F, Liu Z, Wu X, Wu X, Zheng S, Chen N, He L, Ren L, Ni Z, Li D, Liang P, Lv X, Zhang Y. Li Y, et al. Ann Med. 2021 Dec;53(1):217-226. doi: 10.1080/07853890.2020.1861322. Ann Med. 2021. PMID: 33331182 Free PMC article. Clinical Trial.
METHODS: In this randomized, active-controlled clinical trial, the patients with acute uncomplicated UTI were randomized to receive sitafloxacin 100-mg once-daily (qd) or levofloxacin 500-mg qd orally for 3-5 days. The patients with complicated UTI were randomized to recei …
METHODS: In this randomized, active-controlled clinical trial, the patients with acute uncomplicated UTI were randomized to receive sitaflox …
Efficacy And Cost-Effectiveness, Comparison Of 7-Days Vonoprazan Versus 14-Days Esomeprazole Based Triple Therapies For Treating Helicobacter Pylori Infection In Pakistani Population: A Randomized Clinical Trial.
Waqar F, Noor M, Farhat K, Ali S, Haider E, Fatima Gillani SF. Waqar F, et al. J Ayub Med Coll Abbottabad. 2023 Oct-Dec;35(Suppl 1)(4):S746-S751. doi: 10.55519/JAMC-S4-12110. J Ayub Med Coll Abbottabad. 2023. PMID: 38406904 Free article. Clinical Trial.
The Esomeprazole group received 14 days of triple therapy orally with Esomeprazole 20 mg twice a day; Amoxicillin 1000 mg twice a day; and Levofloxacin 500 mg one time a day. The comparative Vonoprazan group was given 7-days triple therapy orally with Vonoprazan 20 mg twic …
The Esomeprazole group received 14 days of triple therapy orally with Esomeprazole 20 mg twice a day; Amoxicillin 1000 mg twice a day; and …
Prevalence and trends of multiple antimicrobial resistance of Helicobacter pylori in one tertiary hospital for 20 years in Korea.
Lee JW, Kim N, Choi SI, Jang JY, Song CH, Nam RH, Lee DH. Lee JW, et al. Helicobacter. 2023 Feb;28(1):e12939. doi: 10.1111/hel.12939. Epub 2022 Dec 7. Helicobacter. 2023. PMID: 36478622 Clinical Trial.
MIC test was performed for amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, and moxifloxacin using agar dilution method. Trends in MIC distribution, prevalence of resistances with single and multiple were investigated which were suspected to be relat …
MIC test was performed for amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, and moxifloxacin using agar diluti …
Levofloxacin pharmacokinetics in children.
Chien S, Wells TG, Blumer JL, Kearns GL, Bradley JS, Bocchini JA Jr, Natarajan J, Maldonado S, Noel GJ. Chien S, et al. J Clin Pharmacol. 2005 Feb;45(2):153-60. doi: 10.1177/0091270004271944. J Clin Pharmacol. 2005. PMID: 15647407 Clinical Trial.
Levofloxacin is a broad-spectrum fluoroquinolone antibiotic with activity against many pathogens that cause bacterial infections in children, including penicillin-resistant pneumococci. ...Each child received a single 7-mg/kg dose of levofloxacin (not to exceed 500 …
Levofloxacin is a broad-spectrum fluoroquinolone antibiotic with activity against many pathogens that cause bacterial infections in c …
Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial.
Song Z, Suo B, Tian X, Ren X, Xue Y, Niu Z, Zhou L. Song Z, et al. Dig Liver Dis. 2023 May;55(5):601-607. doi: 10.1016/j.dld.2022.12.019. Epub 2023 Jan 14. Dig Liver Dis. 2023. PMID: 36646526 Clinical Trial.
METHODS: 800 treatment-naive patients were randomly assigned to four groups receiving clarithromycin-, levofloxacin- or metronidazole-containing empiric TBT and tailored TBT (clarithromycin and levofloxacin chosen based on previous macrolides and quinolones medicati …
METHODS: 800 treatment-naive patients were randomly assigned to four groups receiving clarithromycin-, levofloxacin- or metronidazole …
Ciprofloxacin versus levofloxacin prophylaxis in hematopoietic stem cell transplantation: A randomized trial.
Farhan S, Mazur I, Hartzell S, Xie P, Neme K, German A, Mikulandric N, Patel K, Wu M, Kortam N, Yaseen A, Sweidan A, Latack K, Emole J, Peres E, Abidi MH, Ramesh M. Farhan S, et al. Int J Infect Dis. 2024 Oct;147:107172. doi: 10.1016/j.ijid.2024.107172. Epub 2024 Jul 15. Int J Infect Dis. 2024. PMID: 39019103 Free article. Clinical Trial.
RESULTS: Between June 4, 2018, and May 23, 2022, we randomly assigned 308 consecutive patients to receive ciprofloxacin (154 patients) or levofloxacin (154 patients). BSI was similar in both the ciprofloxacin and levofloxacin groups (18 [11.7%] vs 18 [11.7%]). Pneum …
RESULTS: Between June 4, 2018, and May 23, 2022, we randomly assigned 308 consecutive patients to receive ciprofloxacin (154 patients) or …
1,400 results